Menu

This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information
Male runner with one shoe at mile 8 Male runner with one shoe at mile 6 Male runner with one shoe at mile 7

IN THE MARATHON OF MYELOMA TREATMENT,

ARE YOU DROPPING THE PROTEASOME INHIBITOR TOO SOON?

Continuous treatment with a proteasome inhibitor (PI)–based regimen is associated with clinical benefits, including for patients with high-risk cytogenetics.1-3 However, many patients who have had 1 prior therapy receive injectable PIs for only 4 to 7 months.4,5

The NINLARO® (ixazomib) regimen extended median PFS by ~6 months (median: 20.6 vs 14.7 months) vs placebo regimen in patients with multiple myeloma who have received at least 1 prior therapy.1*†

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

SEE THE PATH TO EXTENDED PFS
VIEW SAFETY